A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

An update from Vivani Medical ( (VANI) ) is now available. Vivani Medical is advancing its innovative GLP-1 implant technology to address ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite.

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

"Our progress in the third quarter was highlighted by the compelling topline results from our Phase 1 study of TERN-601, ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...